Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial by Alexey V. Danilov, Hongli Li, Mazyar Shadman, Lisa Rimsza, Ahmad Zebari, Sonali M. Smith, Michael LeBlanc, Jonathan W. Friedberg, Christopher Carlson, Joo Y. Song

Get full text

Phase 1 trial of durvalumab (anti–PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma by Christiane Querfeld, Joycelynne Palmer, Zhen Han, Xiwei Wu, Yate-Ching Yuan, Min-Hsuan Chen, Chingyu Su, Ni-Chun Tsai, D. Lynne Smith, Samantha N. Hammond, Liliana Crisan, Joo Y. Song, Raju Pillai, Steven T. Rosen, Jasmine Zain

Get full text

CEACAM1 as a mediator of B-cell receptor signaling in mantle cell lymphoma by Serene Xavier, Vivian Nguyen, Vishal Khairnar, An Phan, Lu Yang, Michael S. Nelson, Ravi P. Shukla, Jinhui Wang, Aimin Li, Huimin Geng, Jaewoong Lee, Teresa Sadras, Lan V. Pham, Dennis D. Weisenburger, Wing C. Chan, Karl S. Lang, Geoffrey P. Shouse, Alexey V. Danilov, Joo Y. Song, Samir Parekh, Markus Müschen, Vu N. Ngo

Get full text